Literature DB >> 23504991

Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population.

Nicolas R Smoll1, Oliver P Gautschi, Ivan Radovanovic, Karl Schaller, Damien C Weber.   

Abstract

BACKGROUND: Chordomas are rare bone tumors arising from remnants of the embryonic notochord.
METHODS: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (1973-2009) to calculate the incidence, relative survival (RS), and standardized mortality ratio (SMR) of patients diagnosed with intracranial and extracranial chordomas and to assess the effects of age and sex on this disease.
RESULTS: The overall incidence of extracranial and intracranial chordomas was 8.4 per 10 million population. The median overall survival of patients with chordoma patients was 7.7 years. The median survival was 7.7 years for male patients and 7.8 years for female patients. Younger patients (aged <40 years) survived longer compared with older patients (10-year RS, 68% vs 43%). The estimated age-standardized 5-year, 10-year, and 20-year RS rates was 72%, 48%, and 31%, respectively. The SMR in the overall cohort was 4.6 (95% confidence interval, 4.22-5.0) or 21.0 (95% confidence interval, 16.6-27.2) in young adult patients and 3.0 (95% confidence interval, 2.6-3.4) in elderly patients.
CONCLUSIONS: The elderly had a more aggressive form of this disease; and, other than the incidence, sex did not influence outcome in this disease. The study of chordomas presents a good case for the contribution that the SMR can have on measuring the impact of a disease on a population of patients. Although the younger population has better survival rates, the impact (SMR) in the younger age groups is much higher than in older populations.
Copyright © 2013 American Cancer Society.

Entities:  

Mesh:

Year:  2013        PMID: 23504991     DOI: 10.1002/cncr.28032

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  77 in total

1.  Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.

Authors:  Dilys M Parry; Mary L McMaster; Norbert J Liebsch; Nicholas J Patronas; Martha M Quezado; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein
Journal:  J Neurosurg       Date:  2020-06-19       Impact factor: 5.115

2.  MR Imaging Grading System for Skull Base Chordoma.

Authors:  K Tian; L Wang; J Ma; K Wang; D Li; J Du; G Jia; Z Wu; J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

3.  Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.

Authors:  Michael J Kelley; Jianxin Shi; Bari Ballew; Paula L Hyland; Wen-Qing Li; Melissa Rotunno; David A Alcorta; Norbert J Liebsch; Jason Mitchell; Sara Bass; David Roberson; Joseph Boland; Michael Cullen; Ji He; Laurie Burdette; Meredith Yeager; Stephen J Chanock; Dilys M Parry; Alisa M Goldstein; Xiaohong R Yang
Journal:  Hum Genet       Date:  2014-07-04       Impact factor: 4.132

4.  Analysis of variants at LGALS3 single nucleotide polymorphism loci in skull base chordoma.

Authors:  Kaibing Tian; Liang Wang; Ke Wang; Junpeng Ma; Da Li; Yang Yang; Guijun Jia; Zhen Wu; Liwei Zhang; Junting Zhang
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

5.  STAT3 Inhibition as a Therapeutic Strategy for Chordoma.

Authors:  Anthony C Wang; John H Owen; Waleed M Abuzeid; Shawn L Hervey-Jumper; Xiaobing He; Mikel Gurrea; Meijuan Lin; David B Altshuler; Richard F Keep; Mark E Prince; Thomas E Carey; Xing Fan; Erin L McKean; Stephen E Sullivan
Journal:  J Neurol Surg B Skull Base       Date:  2016-05-31

Review 6.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

Review 7.  Soft Tissue Special Issue: Chondroid Neoplasms of the Skull.

Authors:  A N Flaman; J K Wasserman; D H Gravel; B M Purgina
Journal:  Head Neck Pathol       Date:  2020-01-16

8.  Treatment and Outcome of Patients with Skull Base Chordoma: A Meta-analysis.

Authors:  Moran Amit; Shorook Na'ara; Yoav Binenbaum; Salem Billan; Gil Sviri; Jacob T Cohen; Ziv Gil
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-27

9.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.

Authors:  Chetan Bettegowda; Stephen Yip; Sheng-Fu Larry Lo; Charles G Fisher; Stefano Boriani; Laurence D Rhines; Joanna Y Wang; Aron Lazary; Marco Gambarotti; Wei-Lien Wang; Alessandro Luzzati; Mark B Dekutoski; Mark H Bilsky; Dean Chou; Michael G Fehlings; Edward F McCarthy; Nasir A Quraishi; Jeremy J Reynolds; Daniel M Sciubba; Richard P Williams; Jean-Paul Wolinsky; Patricia L Zadnik; Ming Zhang; Niccole M Germscheid; Vasiliki Kalampoki; Peter Pal Varga; Ziya L Gokaslan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

10.  Unusual Presentation of Chordoma in Nose.

Authors:  Divya Gupta; Praveen Kumar Rathore; Anju Chauhan; Nita Khurana
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2015-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.